...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.
【24h】

Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.

机译:基于蒽环类的化疗后,患有3级滤泡性淋巴瘤的患者可延长无复发生存期:内布拉斯加州淋巴瘤研究小组的经验。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3). Materials and methods: Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study. RESULTS: Patients with FL3 and a diffuse component of >50% had the worst outcome, with a hazard ratio of dying of 2.2 (95% CI 1.4-3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95% CI 1.02-2.5) compared with FL3 with a diffuse component of
机译:摘要背景:这项研究的目的是确定积极治疗的滤泡性淋巴瘤(FL)患者的预后结果和临床特征,并确定3级FL(FL3)患者的疾病特异性死亡率。资料和方法:回顾性研究纳入了421例接受各种蒽环类化疗方案治疗的FL患者。结果:FL3和弥散成分> 50%的患者预后最差,与FL1或FL2的患者相比,死亡风险比为2.2(95%CI 1.4-3.4),比率为1.6(95%)多元分析(P = 0.0026)得出的扩散成分为

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号